News Releases

» RusnanoMedInvest and Domain Associates Invest In Neurology Company Marinus Pharmaceuticals
» Marinus Pharmaceuticals Issued Patent for Ganaxolone
» Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome
» Marinus Pharmaceuticals Adds Two Life Sciences Veterans to its Board of Directors
» Marinus Pharmaceuticals Raises $20 Million in Series B Financing
» Marinus Pharmaceuticals, Inc. Announces Positive Results of its Phase 2 Clinical Trial of Ganaxolone as Adjunctive Therapy in Adults with Partial Onset Seizures
» Marinus Pharmaceuticals, Inc., Completes Two Phase 2 Milestones for Ganaxolone in Epilepsy
» Marinus Pharmaceuticals Appoints John Krayacich as President and Chief Executive Officer
» Marinus Pharmaceuticals Initiates Phase IIb Study of Ganaxolone for Adult Partial Seizures
» Marinus Pharmaceuticals Initiates Phase IIb Study of Ganaxolone for Infantile Spasms
» Marinus Pharmaceuticals completes a $29.4 million Series A financing round